Is There a Difference in Demography and Clinical Characteristics in Patients Treated With and Without Bevacizumab?

被引:8
作者
Hartmann, Holger [1 ]
Mueller, Judith [1 ]
Marschner, Norbert
机构
[1] iOMEDICO, Freiburg, Germany
关键词
D O I
10.1200/JCO.2012.43.3409
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:3317 / 3318
页数:3
相关论文
共 4 条
[1]   Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE) [J].
Grothey, Axel ;
Sugrue, Mary M. ;
Purdie, David M. ;
Dong, Wei ;
Sargent, Daniel ;
Hedrick, Eric ;
Kozloff, Mark .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) :5326-5334
[2]   Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer [J].
Meyerhardt, Jeffrey A. ;
Li, Ling ;
Sanoff, Hanna K. ;
Carpenter, William ;
Schrag, Deborah .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) :608-615
[3]  
National Comprehensive Cancer Network, NEW TREATM OPT FEAT
[4]  
Quigley J, 2006, 2006 GASTR CANC S FR